Suggested blood donor deferral strategy regarding hepatitis B infections in China
Transfusion Medicine · 2024
DOI: 10.1111/tme.13030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion Medicine, 2024. Verfasst von Ling Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Transfusion, The Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu, People's Repu…. Hauptthemen laut MEDLINE: Hepatitis B Core Antigens, Hepatitis B. Die Arbeit nennt 7 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences, Science & Technology Department of Sichuan Province, The Third People's Hospital of Chengdu Scientific Research Project.
Abstract (Originalsprache)
Background
Hepatitis B virus (HBV) reactivity in individual immunologic and nucleic acid tests (NAT) tests does not represent the true infectious status of the blood donor. This study discusses the use of confirmatory tests to determine when deferral of blood donors is appropriate.
Methods
HBsAg or HBV NAT reactive samples were confirmed via a neutralisation test. All the HBsAg reactive but neutralisation test negative samples were subjected to further anti‐HBc testing. The receiver operating characteristic curve was used to obtain the best threshold value using signal‐to‐cut‐off ratios of two HBsAg enzyme‐linked immunosorbent assay reagents.
Results
Of the 780 HBV reactive samples collected, there were 467 HBsAg reactive but HBV DNA negative samples, of which 65 (13.92%) and 402 (86.08%) were neutralisation test positive and negative, respectively. Of the 402, 91 samples (30% of tested samples) were anti‐HBc reactive. HBV DNA positive specimens negative by virus neutralisation were >80% HBcAg positive. A screening strategy was proposed for Chinese blood collection agencies.
Conclusion
These findings suggest that adopting a screening algorithm for deferring HBV reactive blood donors based on HBsAg and NAT testing followed with HBsAg S/CO consideration and HBcAg testing can be both safe and feasible in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Blood Transfusion, The Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu, People's Republic of China.
- School of Public Health, Anhui Medical University, Hefei, People's Republic of China.
- Blood Screening Laboratory, Beijing Red Cross Blood Center, Beijing, People's Republic of China.
- Medical Affairs Department, Beijing Red Cross Blood Center, Beijing, People's Republic of China.
- Clinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu, People's Republic of China.
- Blood Components Procession Department, Shenzhen Blood Center, Shenzhen, People's Republic of China.
ORCID-Profile: Zhong Liu
Förderung
- CAMS Innovation Fund for Medical Sciences
- Science & Technology Department of Sichuan Province
- The Third People's Hospital of Chengdu Scientific Research Project
- Science and Technology Department of Sichuan Province
Zitieren
APA
Li, L., Wang, R., Guo, J., He, L., Liu, Z., Qin, Q., Zhang, J., Wu, S., Huang, L., Ge, H., & Liu, Z. (2024). Suggested blood donor deferral strategy regarding hepatitis B infections in China. Transfusion Medicine. https://doi.org/10.1111/tme.13030
Vancouver
Li L, Wang R, Guo J, He L, Liu Z, Qin Q, et al. Suggested blood donor deferral strategy regarding hepatitis B infections in China. Transfusion Medicine. 2024. doi:10.1111/tme.13030
BibTeX
@article{Li2024,
author = {Li, Ling and Wang, Rui and Guo, Jin and He, Liu and Liu, Zhengmin and Qin, Qianqian and Zhang, Jing and Wu, Shuo and Huang, Liqin and Ge, Hongwei and Liu, Zhong},
title = {Suggested blood donor deferral strategy regarding hepatitis B infections in China},
journal = {Transfusion Medicine},
year = {2024},
doi = {10.1111/tme.13030}
}
EUVIMED